Navigation Links
Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
Date:2/2/2009

WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the BIO CEO and Investor Conference on Monday, February 9th, 2009 at 11:30 a.m. EST at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, NY.

A live audio webcast of the presentation will be available via Repligen's website at www.repligen.com and will be archived for 30 days following the presentation.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, pla
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Florida (PRWEB) , ... June 30, 2015 , ... ... cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast ... largest but also the most dynamic collection of legal medical cannabis stories ever ...
(Date:6/29/2015)... 30, 2015   Pharnext SAS today announced that ... the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented ... Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec Congress ... 27 - July 2, 2015. At Poster Viewing ... 1, 5p.m. to 7p.m. EDT: Poster 23: ...
(Date:6/29/2015)... ... June 29, 2015 , ... The global microfluidics market is ... period (2015 to 2020). The market is mainly driven by the rising geriatric ... R&D. However, lack of adequate healthcare and research infrastructure in emerging markets, dearth ...
(Date:6/29/2015)... WASHINGTON , June 29, 2015  AACC, ... to better health through laboratory medicine, is pleased ... journal, Clinical Chemistry , has increased to ... Reports. This increase places Clinical Chemistry ... and reflects the significant influence of the research ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... scientists at the National Institute of Standards and ... highly efficient piezoelectric material into a silicon microelectromechanical ... advances in sensing, imaging and energy harvesting. ... when fed electricity and, conversely, generates an electric ...
... Modern Mobility Aids, Inc. (OTCBB: MDRM) (the "Company") ... financing required to execute its closing agreement to acquire ... ("LumiGene"). Modern Mobility Aids, Inc. is a ... and development in the Bio-Pharma sector as well as ...
... The question of how many polyhedral nanocrystals of silver ... burning on many lips but the answer holds importance ... plasmonics! Researchers with the U.S. Department of Energy (DOE),s ... the door to a simpler approach for the fabrication ...
Cached Biology Technology:Tiny levers, big moves in piezoelectric sensors 2Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 2Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 3On the road to plasmonics with silver polyhedral nanocrystals 2On the road to plasmonics with silver polyhedral nanocrystals 3
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... world would help stave off an imminent global extinction ... Proceedings of the National Academy of Sciences ( www.pnas.org ... member organizations of the Alliance for Zero Extinction (AZE ... with imminent extinction, each of which is in need ...
... has its roots in yielding more food to feed more ... , His team's study appears in ... , The team made tomato plants over-express the gene, ... resulted in roots making better use of limited water, said ...
... and the National Human Genome Research Institute (NHGRI), ... (NIH), today launched a comprehensive effort to accelerate ... through the application of genome analysis technologies, especially ... Cancer Genome Atlas (TCGA), will begin with a ...
Cached Biology News:Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy 2Anyway you slice it, tomatoes cut through drought with new gene 2NIH launches comprehensive effort to explore cancer genomics 2NIH launches comprehensive effort to explore cancer genomics 3NIH launches comprehensive effort to explore cancer genomics 4